X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES SUN PHARMA VENUS REMEDIES/
SUN PHARMA
 
P/E (TTM) x -846.8 15.8 - View Chart
P/BV x 0.2 3.7 6.7% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 VENUS REMEDIES   SUN PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
SUN PHARMA
Mar-16
VENUS REMEDIES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs2181,201 18.2%   
Low Rs82706 11.6%   
Sales per share (Unadj.) Rs365.6117.5 311.3%  
Earnings per share (Unadj.) Rs1.519.6 7.6%  
Cash flow per share (Unadj.) Rs37.923.8 159.3%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.1 0.0%  
Book value per share (Unadj.) Rs382.5130.5 293.2%  
Shares outstanding (eoy) m11.442,406.60 0.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.48.1 5.1%   
Avg P/E ratio x101.048.7 207.5%  
P/CF ratio (eoy) x4.040.1 9.9%  
Price / Book Value ratio x0.47.3 5.4%  
Dividend payout %05.1 0.0%   
Avg Mkt Cap Rs m1,7172,294,813 0.1%   
No. of employees `0001.014.7 6.9%   
Total wages/salary Rs m32447,971 0.7%   
Avg. sales/employee Rs Th4,100.719,169.8 21.4%   
Avg. wages/employee Rs Th318.03,253.0 9.8%   
Avg. net profit/employee Rs Th16.73,197.9 0.5%   
INCOME DATA
Net Sales Rs m4,183282,697 1.5%  
Other income Rs m206,170 0.3%   
Total revenues Rs m4,203288,867 1.5%   
Gross profit Rs m81283,239 1.0%  
Depreciation Rs m41710,135 4.1%   
Interest Rs m3804,769 8.0%   
Profit before tax Rs m3574,505 0.0%   
Minority Interest Rs m0-11,126 0.0%   
Prior Period Items Rs m0-19 0.0%   
Extraordinary Inc (Exp) Rs m0-6,852 0.0%   
Tax Rs m189,349 0.2%   
Profit after tax Rs m1747,159 0.0%  
Gross profit margin %19.429.4 65.9%  
Effective tax rate %51.612.5 410.9%   
Net profit margin %0.416.7 2.4%  
BALANCE SHEET DATA
Current assets Rs m2,771308,646 0.9%   
Current liabilities Rs m1,931132,477 1.5%   
Net working cap to sales %20.162.3 32.2%  
Current ratio x1.42.3 61.6%  
Inventory Days Days12583 150.8%  
Debtors Days Days5488 61.3%  
Net fixed assets Rs m5,328133,606 4.0%   
Share capital Rs m1142,407 4.8%   
"Free" reserves Rs m4,177266,909 1.6%   
Net worth Rs m4,376314,042 1.4%   
Long term debt Rs m1,91131,167 6.1%   
Total assets Rs m8,428542,196 1.6%  
Interest coverage x1.116.6 6.6%   
Debt to equity ratio x0.40.1 439.9%  
Sales to assets ratio x0.50.5 95.2%   
Return on assets %4.79.6 49.2%  
Return on equity %0.415.0 2.6%  
Return on capital %6.617.8 37.2%  
Exports to sales %014.0 0.0%   
Imports to sales %20.53.1 653.1%   
Exports (fob) Rs mNA39,572 0.0%   
Imports (cif) Rs m8588,882 9.7%   
Fx inflow Rs m042,171 0.0%   
Fx outflow Rs m85821,583 4.0%   
Net fx Rs m-85820,588 -4.2%   
CASH FLOW
From Operations Rs m46967,694 0.7%  
From Investments Rs m29-44,549 -0.1%  
From Financial Activity Rs m-464-19,243 2.4%  
Net Cashflow Rs m353,902 0.9%  

Share Holding

Indian Promoters % 32.9 63.7 51.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 5.1 3.5%  
FIIs % 0.6 23.0 2.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 8.3 800.0%  
Shareholders   20,121 133,026 15.1%  
Pledged promoter(s) holding % 36.4 0.5 6,860.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  BIOCON LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Pharma Drug Approvals, Global Updates, Oil Prices, and Top Stocks in Action Today(Pre-Open)

Indian share markets snapped their losing streak seen during last week and closed their Wednesday session on a positive note.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 16, 2017 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS